NAV
$28.96
AUM
$227.0M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.00
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +16.85% | +7.29% | +15.98% | +9.26% | - | - |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | LRCX | Lam Research Corp | 6.22% |
| 2 | LLY | Eli Lilly and Co | 5.94% |
| 3 | MNST | Monster Beverage Corp | 5.76% |
| 4 | AMAT | Applied Materials Inc | 5.76% |
| 5 | LMT | Lockheed Martin Corp | 5.16% |
| 6 | CAH | Cardinal Health Inc | 5.15% |
| 7 | GD | General Dynamics Corp | 5.07% |
| 8 | IDXX | IDEXX Laboratories Inc | 5.06% |
| 9 | NDSN | Nordson Corp | 5.02% |
| 10 | GOOGL | Alphabet Inc Class A | 5.00% |
The fund is actively managed and typically owns 20 domestic stocks that are normally included in the S&P 500 Index (“S&P 500”). The FCT strategy is based on a proprietary model developed by 3Fourteen that selects stocks based on quality stock screens and trend factors such as return on capital and cash flow stability, earnings growth, return on investment, momentum, linear regression and trend analysis. The fund is non-diversified.
Inception Date: 2024-07-01